MDGL

Madrigal Pharmaceuticals, Inc. [MDGL] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

MDGL Stock Summary

Top 10 Correlated ETFs

MDGL

Top 10 Correlated Stocks

MDGL

In the News

MDGL Financial details

Company Rating
-
Market Cap
4.97B
Income
-374.53M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
376
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-12.56
Forward P/E
-
PEG
-8.71
P/S
-
P/B
197.6
P/C
-
P/FCF
-15.49
Quick Ratio
2.33
Current Ratio
2.36
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-19.99
EPS next Y
-
EPS next Q
-
EPS this Y
14.42%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
6.37%
-
-
-
-
SMA20
-6.79%
SMA50
-24.83%
SMA100
1.86%
Inst Own
-
Inst Trans
-
ROA
-147%
ROE
-296%
ROC
-2.52%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
119.76-322.67
52W High
+37.32%
52W Low
+271.57%
RSI
46
Rel Volume
0.32
Avg Volume
576.5K
Volume
187.33K
Perf Week
2.17%
Perf Month
-7.61%
Perf Quarter
4.53%
Perf Half Y
3.89%
-
-
-
-
Beta
-0.437
-
-
Volatility
4.13%, 20.04%
Prev Close
-0.23%
Price
442.165
Change
-0.77%

Something similar

Top by Market Cap
BRH.DE
APC.DE
0YXG.L
DHR-PB
ABEC.DE
Top Correlated ETFs
XUT3.L
PPEM
PBDC
FTSL
DGZ
Top Correlated Stocks
MBRX
CAR
0HK4.L
NPACY
EAT
Similar Market Cap
JFNSX
000838.SZ
600713.SS
SNC.TO
603363.SS

Company Profile

Healthcare Biotechnology
  • Volume Average 576.5K
  • Market Capitalization 4.97B
  • Employee 376
  • CEO Mr. William J. Sibold
  • Headquarters West Conshohocken,PA,US
  • IPO Date 2007-02-06
  • Website https://www.madrigalpharma.com

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.